Migraine. Migraine
Conditions
Interventions
Topiramate 25 mg/d will be prescribed for the patients in the first week and will be increased 25 mg/d weekly (up to 100 mg/d) and the maximum dose will be continued for 3 months.
Treatment - Drugs
Topiramate 25 mg/d will be prescribed for the patients in the first week and will be increased 25 mg/d weekly (up to 100 mg/d) and the maximum dose will be continued for 3 months
Sponsors
Vice chancellery for research, Isfahan university of medical sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: diagnosed for migraine based on the International Headache Society (IHS) criteria by a neurologist, having headache not more than 14 days per month, a history of 3 to 12 attacks. Exclusion criteria: non-migraine headaches such as tension and sinus headaches, severe depression and a history of medical diet failure.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The clinical status of patient's migraine according to HIT6 questionnaire. Timepoint: beginning and end of the study (after 3 months). Method of measurement: history and physical exam.;The clinical status of patient's migraine according to MIDAS questionnaire. Timepoint: beginning and end of the study (after 3 months). Method of measurement: history and physical exam. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects of Topiramate in patients. Timepoint: end of the study (after 3 months). Method of measurement: history and physical exam. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyed Ali Sonbolestan
Isfahan university of medical sciences
Outcome results
None listed